{"id":"NCT01251367","sponsor":"Ipsen","briefTitle":"Dysport® Adult Lower Limb Spasticity Follow-on Study","officialTitle":"A Phase III, Prospective, Multicentre, Open Label, Extension Study, to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Lower Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2015-04","completion":"2015-04","firstPosted":"2010-12-01","resultsPosted":"2017-11-09","lastUpdate":"2022-09-28"},"enrollment":352,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Post-stroke Spasticity","Spasticity Post-Traumatic Brain Injury"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]}],"arms":[{"label":"Dysport®","type":"EXPERIMENTAL"}],"summary":"The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.","primaryOutcome":{"measure":"Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to EOS (maximum duration of 52 weeks).","effectByArm":[{"arm":"Total Dysport®","deltaMin":140,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":50,"countries":["United States","Australia","Belgium","Czechia","France","Hungary","Italy","Poland","Portugal","Russia","Slovakia"]},"refs":{"pmids":["32741133","32108436","31529136","29093068"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":43,"n":345},"commonTop":["Fall","Muscular weakness"]}}